Celcuity 

Operating as a clinical-stage biotechnology company, Celcuity Inc. is dedicated to pioneering precision cancer treatments for patients across the United States. At the heart of their approach is the CELsignia diagnostic platform, which examines live tumor cells from patients. This innovative system aims to uncover the precise cellular dysfunction fueling an individual's cancer, thereby guiding the selection of the most appropriate targeted therapeutic intervention. Among its pipeline of drug candidates is Gedatolisib, an agent engineered to selectively inhibit class I PI3K isoforms and mammalian target of rapamycin (mTOR). This therapy is being developed specifically for advanced or metastatic breast cancer patients who are hormone receptor positive and HER2-negative. Celcuity is also advancing the CELsignia MP test, a qualitative lab-developed assay designed to quantify HER2, c-Met, and PI3K signaling activity within both breast and ovarian tumor cells. The company secured a licensing agreement with Pfizer, Inc. for the development and commercialization rights pertaining to Gedatolisib. Established in 2011, Celcuity Inc. maintains its corporate headquarters in Minneapolis, Minnesota.